• br Theoretical mechanism of ABCA activity in LE LY

  2024-01-05

  

  Theoretical mechanism of ABCA2 activity in LE/LY in modulation of cholesterol trafficking It is important to confirm that ABCA2 is a lipid transporter and identify the substrates that are mechanistic in its cholesterol sequestering activity. We hypothesize that ABCA2 modulates cholesterol sequest

• The hypothalamic pituitary adrenal HPA axis is a neuroendocr

  2024-01-05

  

  The hypothalamic-pituitary-adrenal (HPA) axis is a neuroendocrine system that is central to regulating responses to stress (Palazidou, 2012). In older persons, a high dysfunction of the HPA axis is observed (Otte et al., 2005) which may be enhanced by stimulatory effects of genes involved in the axi

• Inhibitors of mPGES are considered as safe

  2024-01-05

  

  Inhibitors of mPGES-1 are considered as safe alternative to NSAIDs in the treatment of chronic inflammatory diseases that are characterized by excessive PGE2 production (Bahia et al., 2014; Khurana and Jachak, 2016; Koeberle et al., 2016; Korotkova and Jakobsson, 2014; Norberg et al., 2013; Psarra e

• br Diabetes and obesity fit

  2024-01-05

  

  Diabetes and obesity: fit or fat; sugar or not: the autophagic verdict Type 2 diabetes and obesity are among the most emerging health problems worldwide. The factors that are responsible for the establishment of diabetes include decreased bioactive production, rise in adiposity, and an increase

• br Aromatase the key enzyme for estrogen

  2024-01-05

  

  Aromatase: the key enzyme for estrogen formation in adipose tissue Estrogens are synthesized from androgens by aromatase, a member of the cytochrome P450 superfamily, which is the rate-limiting enzyme in estrogen biosynthesis (Santen et al, 2009, Simpson et al, 1994). At the cellular level, aroma

• Interestingly we noticed that LPS

  2024-01-04

  

  Interestingly, we noticed that LPS exposure was associated with decreased phosphorylation of AMPK and increased phosphorylation of p70S6K1, suggesting that AMPK inactivation and the subsequent mTOR activation might be involved in the development of LPS-induced inflammation. On the other side, treatm

• The lactam emerged as lead candidate due to its high

  2024-01-04

  

  The lactam (6) emerged as lead candidate due to its high selectivity, outstanding potency (against ALK or in clinically known ALK mutants), low in vitro clearance, and low efflux potential. The lactam (6) was selected for further profiling against the resistant ALK mutants. Preclinical rat pharmacok

• As noted earlier the PfkB family of

  2024-01-04

  

  As noted earlier, the PfkB family of carbohydrate kinases can phosphorylate the hydroxymethyl group of a wide variety of sugar moieties [1], [3]. Recent searches of the Swiss-Prot database with the two conserved sequence motifs found in these proteins (Accession nos. PS00583 and PS00584) identified

• Tacrine an aminoacridine derivative Fig A was the first AChE

  2024-01-04

  

  Tacrine, an aminoacridine derivative (Fig. 1, A), was the first AChE inhibitor approved for treatment of AD [12], [13]. This compound was withdrawn from the market due to its hepatotoxicity [14]. In spite of tacrine's side effects, it is still an attractive lead compound for medicinal chemists due t

• br Acknowledgments br Introduction Hypospadias is

  2024-01-04

  

  Acknowledgments Introduction Hypospadias is a common congenital malformation in males, in which the urethral orifice is found on the ventral side of the penis as a result of incomplete fusion of urethral folds. The mean prevalence in per 10,000 live births from 1910 to 2013 were: Europe 19.9,

• br Acknowledgments br Introduction Hypospadias is

  2024-01-04

  

  Acknowledgments Introduction Hypospadias is a common congenital malformation in males, in which the urethral orifice is found on the ventral side of the penis as a result of incomplete fusion of urethral folds. The mean prevalence in per 10,000 live births from 1910 to 2013 were: Europe 19.9,

• br Conclusions and future direction ER PgR breast cancers

  2024-01-03

  

  Conclusions and future direction ER(−)/PgR(+) breast cancers have a distinct clinical course, response to treatment, and molecular features when compared to other breast cancer types, however some of them are actually technical artifacts or consequences of too high definitions of positivity. Acco

• In summary present evidence suggests that

  2024-01-03

  

  In summary, present evidence suggests that antimicrobial therapy for intra-abdominal sepsis can be shortened in patients exhibiting a clinical response to treatment. Hence, clinicians should use the resolution of clinical signs of infection as a guide to determine when during the 4–7-day window anti

• br Concluding Remarks Despite major advances

  2024-01-03

  

  Concluding Remarks Despite major advances in the development of antibody and small-molecule tumor angiogenesis inhibitors, therapy resistance, both innate and acquired, continues to limit further survival improvements for patients with cancer. Preclinical models of localized primary tumors and me

• br Nanoparticle Conjugated Topoisomerase Inhibitors

  2024-01-03

  

  Nanoparticle-Conjugated Topoisomerase Inhibitors The safety and efficacy of topotecan administered as LDM or MTD have been evaluated in several preclinical studies and a few clinical trials whose results showed that there can be significant adverse effects likely precluding its use in patients [5

16441 records 242/1097 page Previous Next First page 上5页 241242243244245 下5页 Last page